Abstract:Unhealthy lifestyle habits including a sedentary life, the lack of physical activity, and wrong dietary habits are the major ones responsible for the constant increase of obesity and metabolic disorders prevalence worldwide; therefore, the scientific community pays significant attention to the pharmacotherapy of such diseases, beyond lifestyle interventions, the use of medical devices, and surgical approaches. The intricate interplay between autophagy and inflammation appears crucial to orchestrate fundamental aspects of cellular and organismal responses to challenging stimuli, including metabolic insults; hence, when these two processes are dysregulated (enhanced or suppressed) they produce pathologic effects. The present review summarizes the existing literature reporting the intricate affair between autophagy and inflammation in the context of metabolic disorders, including obesity, diabetes, and liver metabolic diseases (non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)). The evidence collected so far suggests that an alteration of autophagy might lead to maladaptive metabolic and inflammatory responses thus exacerbating the severity of the disease, and the most prominent conclusion underlies that autophagy might exert a protective function by contributing to balance inflammation. However, the complex nature of obesity and metabolic disorders might represent a limit of the studies; indeed, although many pharmacological treatments, producing positive metabolic effects, are also able to modulate autophagic flux and inflammation, it is not clear if the final beneficial effect might occur only by their mechanism of action, rather than because of additionally involved pathways. Finally, although future studies are needed, the observation that anti-obesity and antidiabetic drugs already on the market, including incretin mimetic agents, facilitate autophagy by dampening inflammation, strongly contributes to the idea that autophagy might represent a druggable system for the development of novel pharmacological tools that might represent an attractive strategy for the treatment of obesity and metabolic disorders.

Autophagy is an inflammation-related defensive mechanism against disease

Autophagy and proinflammatory cytokines: Interactions and clinical implications.

Interactions of Autophagy and the Immune System in Health and Diseases

Autophagy and Inflammatory Diseases

Autophagy balances inflammation in innate immunity

Advances in the interaction of autophagy with inflammatory response

Autophagy in autoimmune disease

Regulation of Energy Balance by Inflammation: Common Theme in Physiology and Pathology

Therapeutic Potential of Autophagy in Immunity and Inflammation: Current and Future Perspectives

Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?

Modulation of the Immunity and Inflammation by Autophagy

Autophagy induction: a critical event for the modulation of cell death/survival and inflammatory responses by adipokines

Harnessing the crosstalk of adipocytes, autophagy, and immune cells for immunotherapy in obesity

Autophagy and Macrophage Functions: Inflammatory Response and Phagocytosis

The inflammation highway: metabolism accelerates inflammatory traffic in obesity

Regulation of interferon signaling in response to gut microbes by autophagy

Impact of Autophagy of Innate Immune Cells on Inflammatory Bowel Disease

Autophagy: A Crucial Moderator of Redox Balance, Inflammation, and Apoptosis in Lung Disease

Autophagy in infection

Interplay Between Autophagy and Inflammasomes

Intestinal epithelium and autophagy: partners in gut homeostasis